Nanobiotix Earnings Call: Deeper J&J Ties, Lower Loss

Nanobiotix SA ((FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nanobiotix SA’s latest earnings call struck a cautiously optimistic tone as management highlighted operational momentum, a cleaner balance sheet and visible trial progress under its Johnson & Johnson partnership. At the same time, executives underscored that much of the 2025 financial uplift stems from one-off items and that future value creation hinges on J&J’s decisions and contingent cash inflows.

J&J Collaboration Drives Late-Stage Pipeline Progress

Nanobiotix emphasized the strategic transfer of the Phase III NANORAY-312 head and neck trial to Johnson & Johnson, which now sponsors, operates and funds the study. The CONVERGE Phase II trial in unresectable Stage III lung cancer delivered promising safety lead-in data, with 5 of 7 patients responding and full disease control, though management stressed the small sample size and the need to wait for randomized data in 2027.

One-Time Revenue Boost Masks Underlying Trends

The company reported 2025 revenue of €32.6 million versus a negative €7.2 million in 2024, a turnaround that on the surface suggests strong top-line momentum. However, Nanobiotix clarified that €21.8 million of this figure comes from a nonrecurring accounting impact tied to a March 2025 amendment of the Janssen licensing agreement, limiting its relevance as a baseline for future revenue.

R&D Spend Drops Sharply After Trial Handover

Research and development expenses fell to €23.1 million in 2025 from €40.5 million a year earlier, a roughly 43% decline that reflects the removal of Nanoray-312 funding obligations after transfer to J&J. Management positioned this leaner cost base as a key element of improved financial flexibility, even as they signaled that investments will rise again as newer platforms advance.

Net Loss Narrows Significantly

Nanobiotix’s net loss attributable to shareholders improved to €24.0 million, or €0.50 per share, from €68.1 million, or €1.44 per share, in 2024, representing about a 65% reduction. This improvement was driven by the noncash revenue adjustment from the Janssen deal and the sharp drop in R&D costs, signaling a much lower burn in the near term.

Nondilutive Financing Strengthens Liquidity

The company highlighted a nondilutive royalty financing of up to $71 million with Healthcare Royalty Partners as a central pillar of its capital strategy. Cash and cash equivalents ended 2025 at €52.8 million, up from €49.7 million, and management expects this, plus the remaining $21 million tranche anticipated in late 2026, to fund operations into early 2028.

Curadigm Platform Gains Technical and Partner Traction

Beyond its lead radiotherapy enhancer, Nanobiotix reported steady progress on the Curadigm nanoprimer platform, including four new patent applications and the initiation of CMC work and GMP manufacturing. More than 20 material transfer agreements with pharma and biotech partners across oncology, rare diseases and CNS were signed, with additional updates promised before the end of summer.

Investigator-Sponsored Trials Build Clinical Depth

Several investigator-sponsored trials, including studies at MD Anderson, completed enrollment in 2025, setting up a series of data readouts through 2026 and 2027. Management pointed to four clinical trial results expected this year, three from already completed studies, which could further validate the NBTXR3 platform across multiple tumor types.

Index Inclusion Enhances Market Visibility

Nanobiotix noted its addition to the Euronext SBF 120 index in 2025, a milestone that can increase exposure to institutional investors and passive funds. The company expects that this heightened visibility may improve trading liquidity and broaden the shareholder base, potentially supporting future capital-raising flexibility.

Revenue Quality and Clinical Data Caveats

The call repeatedly stressed that the 2025 revenue jump is largely nonrecurring and does not reflect a new commercial run-rate, which may temper enthusiasm about immediate top-line growth. Similarly, management urged caution in interpreting CONVERGE’s 5-of-7 response rate, given the very small safety lead-in cohort and the need to await randomized Phase II results.

Reliance on Johnson & Johnson for Key Decisions

A central risk theme was Nanobiotix’s dependence on J&J for late-stage development, regulatory filing and indication expansion of JNJ-1900/NBTXR3. The company acknowledged it cannot predict whether positive Phase II data will be sufficient for regulatory action or whether J&J will choose to run additional Phase III trials, leaving timelines and scope of commercialization uncertain.

Runway and Spending Plans Remain Partly Contingent

Management’s projected cash runway into early 2028 assumes receipt of the remaining $21 million from the royalty financing in the fourth quarter of 2026, as well as potential milestone inflows. They also flagged that Curadigm and other platforms will require rising R&D and manufacturing outlays, while declining to provide detailed multi-year burn guidance, adding some uncertainty to future cash needs.

Guidance and Clinical Milestones Ahead

For investors, the company framed 2025 as a year of financial reset, with reported revenue of €32.6 million, sharply reduced R&D at €23.1 million, stable SG&A at €20.4 million and a net loss narrowed to €24 million. Looking ahead, management pointed to key catalysts including the Phase III NANORAY-312 readout in the first half of 2027, CONVERGE randomized results at the beginning of 2027, multiple investigator-sponsored trial readouts this year and further Curadigm updates before summer’s end.

Nanobiotix’s earnings call painted the picture of a company with improved financial breathing room and a high-potential pipeline now largely propelled by a major pharma partner, but also one exposed to partner decisions and contingent financing. For equity investors, the story is increasingly about execution: translating promising early data and a strengthened balance sheet into durable revenue and value over the next two to three years.